Navigation Links
Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Date:11/26/2007

ine. "We are pleased that this distinguished group from Johns Hopkins is supporting our efforts, and we look forward to working with all of our investigators in the coming year to generate clinical data enabling us to assess the potential of bavituximab as a possible new therapy for patients co-infected with HCV and HIV."

This open-label, dose escalation study is expected to enroll up to 24 patients chronically infected with HCV and HIV. Patient cohorts will receive ascending dose levels of bavituximab weekly for up to eight weeks. HCV and HIV viral titers and other biomarkers will be evaluated, although they are not formal study endpoints.

In the United States alone, an estimated 300,000 individuals are co-infected with HCV and HIV, representing up to 30% of all HIV-infected patients. Co-infected patients have been shown to have a lower response to current HCV treatment regimens, and the adverse effects of these regimens can be especially problematic for some HIV patients.

About Bavituximab

Bavituximab is a monoclonal antibody in a new class of anti-phosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses, including both HCV and HIV. Bavituximab helps stimulate the body's immune defenses to destroy both the virus particles and the infected cells. Since bavituximab's PS target comes from the host and not the virus, bavituximab may be less susceptible to the development of anti-viral resistance. Peregrine has completed two bavituximab Phase I monotherapy clinical trials in patients with chronic HCV infection. In these trials, the drug appeared safe and well tolerated with encouraging signs of anti-viral activity. Bavituximab is also in Phase II trials for the treatment of solid cancers.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
(Date:8/29/2014)... As reported by GantDaily.com in the article ... Trends , Outbreaks (8/20), the National Institute on Drug Abuse ... abuse trends by turning to social media. As NIDA currently ... is also working with the University of Maryland to create ... System, which will be funded by the National Institute of ...
(Date:8/29/2014)... Orlando, Florida (PRWEB) August 29, 2014 Formed ... men with talents well beyond their years. Their sophisticated ... avid pop music listener is fortunate enough to experience every ... to leave their audience uplifted and feeling loved with the ... When asked specifically about this, the group unanimously replied - ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Carson Hearing ... to provide hearing health care tips to local residents ... blog section will offer weekly articles from the audiologists ... topics including the latest advances in hearing restoration research, ... questions. The audiologists plan to write a new post ...
(Date:8/29/2014)... August 29, 2014 - Despite US Preventive Services ... are many barriers, several of which may be ameliorated ... researchers at NYU Langone Medical Center published online August ... Medicine ( JGIM ). , David Levine, MD, ... Internal Medicine at NYU Langone, and colleagues found that ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 2Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 4Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 3Health News:Options for weight loss your primary care doctor might not know about 2
... show no lifesaving benefit over bare-metal version, studies show ... arteries propped open by drug-coated stents are less likely ... stents, the risk of death and heart attacks is ... Sweden and the United States show. , The Swedish ...
... Week 2009, Home Care Delivered reinforces programs designed to support clinicians ... ... VA (Vocus) May 6, 2009 -- In conjunction with the American ... observed annually from May 6th through 12th. The week begins with ...
... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...
... 6 Cardinal Health, a global provider of ... productivity of health care, today announced its board ... shareholders to vote on a proposed employee stock ... 99th consecutive regular quarterly dividend.The proposed option exchange ...
... now has within its reach the potential to end ... in Geneva, the Board of Directors of the Global ... today agreed to enhance the Fund,s response to HIV/AIDS ... mother-to-child transmission of HIV (PMTCT), thereby opening the door ...
... Alliance Calls for Cross-Sector Solutions, Releases Strategy ReportWASHINGTON, ... the pharmaceutical industry, patients, consumer groups, and drug ... to counter the continued rise in prescription drug ... result of a combination of factors and can ...
Cached Medicine News:Health News:Drug-Coated Stents Better at Keeping Arteries Open 2Health News:Drug-Coated Stents Better at Keeping Arteries Open 3Health News:Home Care Delivered, Inc. Celebrates National Nurses Week 2009 in Recognition of America's 2.9 Million Registered Nurses 2Health News:Regence Foundation Grants $390,000 to Improve Health Care Safety Net 2Health News:Regence Foundation Grants $390,000 to Improve Health Care Safety Net 3Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 2Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 3Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 4Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 5Health News:GAA Applauds Global Fund's Decision to Accelerate Support for Treatment Strategies to Prevent Mother-to-Child Transmission of HIV 2Health News:Prescription Drug Abuse Poses Public Health Threat 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: